ALK and non-small cell lung carcinoma: Zarogoulidis et al. recruited 74 patients with NSCLC, PD-L1 < or equal to 50%, only adenocarcinoma or squamous cell carcinoma, and all negative for EGFR, ALK, TK1, and BRAF.